Tempus
Precision medicine company (NASDAQ: TEM) whose provider software is what this index covers: Next, an AI clinical decision support system that alerts clinicians to patients who may have fallen off care guidelines, backed by a vendor reported 662 patient prospective study across six sites; Hub, a physician platform rebuilt on an agentic architecture including a prior authorization agent; and David, a generative AI clinical assistant deployed directly into the EHR, with Northwestern Medicine as the first health system. Tempus acquired Deep 6 AI in March 2025, adding a precision research platform that applies natural language processing to structured and unstructured EMR data to match patients to clinical trials in near real time and to generate real world evidence. Deep 6 reports real time EMR feeds across more than 30 health systems, an ecosystem of over 1,000 research facilities including 18 academic medical centers and 11 NCI designated cancer centers, and that sites find more than 25 percent more patients than with traditional recruitment; the company notes 92 percent of trial inclusion and exclusion criteria benefit from unstructured data and that 15 to 20 percent of eligible patients are found through unstructured data alone. Outputs are positioned as decision support requiring trial team validation before action. The sequencing and pharma services businesses are context, not indexed products.
Capability Axes
Graded on the indexed products only. Next is an AI clinical decision support system, Hub runs on an agentic architecture, and David is a generative AI clinical assistant. AI is the mechanism of all three. The broader sequencing and pharma services business is out of scope for this record.
Hub's prior authorization agent gathers guidelines, payer policy, and patient information and outputs support documents for further use by the care team, a human in the loop posture. Northwestern's David deployment includes real time monitoring of deployed algorithms and agents. Oversight is described but not formalized in a published governance framework.
Architecture is described at a marketing level: agentic workflow platform (Agent Builder), multimodal patient record, generative AI assistant. No model cards, named models, or technical documentation retrieved.
Vendor reports a 662 patient prospective study across six sites for Next, with six new indications added in May 2026. Prospective multi site evidence is rare in this index; held back from A because the publication venue and peer review status of the study were not verified.
David is deployed directly into the EHR at Northwestern Medicine, underpinned by a multimodal patient record; Next delivers near real time alerts to clinicians in workflow. Depth demonstrated at a flagship site; breadth of EHR coverage beyond that deployment not documented.
No public pricing. Contact the vendor. Provider software is sold through enterprise and health system contracts with no published rate card.
Announced Deployments
Publicly announced health system deployments and partnerships. This is a record of announcements, not an assessment of deployment success or scale.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise and health system contracts for provider software | — | — | Vendor Published |
Tempus provider software (Next, Hub, David) is sold through enterprise and health system agreements; no rate card is published. Tempus is a public company (NASDAQ: TEM), so segment level economics appear in filings, but product pricing does not.